Contact Us
Drug Search Results
More Filters [+]

Tisagenlecleucel

Alternative Names: tisagenlecleucel, ctl-019, ctl019, ctl 019, Kymriah
Latest Update: 2024-07-23
Latest Update Note: Clinical Trial Update

Product Description

a CD19 CAR T-cell therapy for the treatment of patients with relapsed/refractory large B cell lymphoma (r/r LBCL). (Sourced from: http://neoimmunetech.com/news/page01_view.html?number=55)

Mechanisms of Action: CAR-T,CD19

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tisagenlecleucel

Countries in Clinic: Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Italy, Japan, Korea, Netherlands, Norway, Poland, Romania, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States

Active Clinical Trial Count: 32

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|B-Cell Leukemia|B-Cell Marginal Zone Lymphoma|Composite Lymphoma|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Inflammation|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Lymphoma

Phase 2: Leukemia|Mantle-Cell Lymphoma

Phase 1: Primary Central Nervous System Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CCTL019E2301

P3

Recruiting

Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Follicular Lymphoma

2031-02-20

CCTL019G2201J

P2

Recruiting

Acute Lymphoid Leukemia|B-Cell Leukemia

2028-08-30

LEDA

P3

Recruiting

Follicular Lymphoma

2028-07-24

CASSIOPEIA

P2

Recruiting

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, B-Cell|Acute Lymphoid Leukemia|B-Cell Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma

2027-10-19

57%

Recent News Events

Date

Type

Title

07/05/2024

News Article

 Car T-Cell Therapy Market size is set to grow by USD 3.02 billion from 2024-2028, Growing awareness regarding car T-cell therapy to boost the market growth, Technavio

07/01/2024

News Article

 CAR T-Cell Therapy Market Size Expected to Reach USD 107.92 Billion by 2033

06/27/2024

News Article

 Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market size is set to grow by USD 2.24 billion from 2024-2028, Growing geriatric population boost the market, Technavio

06/14/2024

News Article

 Global Cell and Gene Therapy Market Expected to Grow at 26.4% CAGR, Reaching $23.3 Billion by 2028

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions